The strong subgroup efficacy data supports the accelerated approval narrative, but the confirmatory Phase 3 has not started dosing. Watch for NDA submission in 1H27 and Phase 3 enrollment updates in 1Q27 as key catalysts.
Price Chart
Executive Summary
Cellectar Biosciences reported positive subgroup data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in Waldenström macroglobulinemia patients treated immediately after BTKi therapy, showing 87.5% ORR, 79.2% MRR, and 100% CBR with median DOR of 16 months. The company plans to initiate a confirmatory Phase 3 trial in 1Q27 and submit an NDA for accelerated approval in 1H27. This is a positive clinical update for a late-stage biotech with Breakthrough Therapy designation, but the data is from a small subgroup (n=24) and the confirmatory trial has not yet begun dosing.
Key Facts
- Subgroup analysis (n=24) of patients treated with iopofosine I 131 immediately post-BTKi showed 87.5% ORR, 79.2% MRR, 100% CBR, median DOR 16.0 months, and treatment-free survival of 19.1 months.
- 75% of patients were BTKi refractory; 54% had received multiple BTKi therapies; median 3 prior lines of therapy.
- Phase 3 confirmatory randomized trial in post-first line, post-BTKi population expected to dose first patients in 1Q27; NDA for accelerated approval anticipated in 1H27.
- Iopofosine I 131 has Breakthrough Therapy, six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations from the FDA.
Financial Impact
No financial figures disclosed; clinical-stage company with no approved products or reported revenue.
Risk Factors
- Data is from a small subgroup (n=24) and may not replicate in the larger confirmatory trial.
- Confirmatory Phase 3 has not yet enrolled patients; regulatory approval is uncertain and timeline-dependent.
- Company is pre-revenue and will likely need additional capital to fund the confirmatory trial and NDA submission.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381487 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers